
RAPP Stock Forecast & Price Target
RAPP Analyst Ratings
Bulls say
Rapport Therapeutics is also developing two discovery-stage programs for chronic pain and hearing disorders, both targeting the nicotinic acetylcholine receptor (nAChR). These programs have shown strong pre-clinical data, and if successful in clinical trials, could diversify the company's portfolio and increase its market potential. Moreover, the company operates in the United States, a leading market for pharmaceuticals, providing access to a large patient population and potential for growth.
Bears say
Rapport Therapeutics is a clinical-stage biotechnology company with a portfolio of programs designed to target neurological and psychiatric disorders. With a lead asset in RAP-219, the company has a potential treatment for focal onset seizures, primary generalized tonic-clonic seizures, and bipolar mania. However, the company's reliance on a single asset and the competitive landscape of the psychiatric drug market raise concerns about its long-term success. Additionally, there are uncertainties around the extent of RAP-219's clinical benefit and the potential for side effects, as well as the company's financial stability with a low cash balance and limited revenue at this stage of development.
This aggregate rating is based on analysts' research of Rapport Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
RAPP Analyst Forecast & Price Prediction
Start investing in RAPP
Order type
Buy in
Order amount
Est. shares
0 shares